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There is significant international 
interest in heterologous prime-boost 
COVID-19 vaccination to mitigate 
against supply shocks or shortages 
that might otherwise reduce the speed 
of vaccine roll-out. Additionally, in 
light of changing recommendations 
regarding use of the ChAdOx1 nCoV-19 
(ChAd) COVID-19 vaccine (Vaxzevria, 
AstraZeneca), several countries are now 
advising that individuals previously 
primed with this vaccine should now 
receive an alternative vaccine as 
their second dose, most commonly 
mRNA vaccines such as the BNT162b2 
(BNT) COVID-19 vaccine (Comirnaty, 
Pfizer–BioNTech), administered in a 
heterologous prime-boost schedule.1–3 
To date there are no data on the 
immunogenicity, reactogenicity, or 
safety of such schedules. Com-COV 
(ISRCTN 69254139) is a UK multi-
centre, participant-masked, randomised 
heterologous prime-boost COVID-19 
vaccination study comparing all 
four prime-boost permutations of the 
ChAd and BNT vaccines both at 28-day 
and 84-day prime-boost intervals. 
Participants are 50 years and older with 
no or mild-to-moderate, well controlled 
comorbidity and were recruited across 
eight sites. The protocol is available 
online.
Following consultation with the 
study trial steering committee, here 
we present the initial reactogenicity 
and safety data, ahead of the primary 
immunological outcome, which is 
projected to be available in June, 2021. 
Reactogenicity data presented here 
consist of self-reported solicited local 
and systemic symptoms collected in 
the 7 days after both prime and boost 
vaccination in participants randomised 
to receive vaccines at 28-day intervals. 
Haematology and biochemistry safety 
monitoring blood results are also 
reported from the immunology cohort 
(100 participants with additional 
visits), at baseline (before the prime 
dose), at day 28 (before the boost 
dose) and 7 days post-boost, graded 
according to a modified US Food 
and Drug Administration toxicity 
scale (appendix). All analyses are 
descriptive, as the study was not 
powered for reactogenicity, with 
endpoints reported as frequencies and 
percentages, together with absolute 
differences between heterologous and 
homologous vaccine schedules and 
corresponding 95% CIs.
Recruitment commenced on 
Feb 11, 2021, and was completed on 
Feb 26, 2021, with 830 participants 
enrolled and randomised from 
978 screened (the CONSORT flow 
diagram is available in the appendix). 
463 participants were randomly 
assigned to the four groups with a 
28-day prime-boost interval, and 
367 participants randomised to 
groups with an 84-day prime-boost 
interval. All 463 participants in the 
28-day prime-boost interval group 
received their prime vaccine, and 
461 participants received their boost 
vaccine. Among the 463 participants, 
the median age was 57 years 
(range 50–69), 212 (46%) participants 
were female, and 117 (25%) from 
ethnic minorities, with baseline 
characteristics well balanced across 
study groups. In groups with 
homologous vaccine schedules, 
systemic reactogenicity was greater 
after the prime dose in the ChAd 
group, and after the boost dose in the 
BNT group (figure).
Both heterologous vaccine schedules 
induced greater systemic reactogen-
icity following the boost dose than 
their homologous counterparts, with 
feverishness reported by 37 (34%) 
of 110 recipients of ChAd for prime 
and BNT for boost compared with 
11 (10%) of 112 recipients of ChAd 
for both prime and boost (difference 
24%, 95% CI 13–35%). Feverishness 
was reported by 47 (41%) of 
114 recipients of BNT for prime and 
ChAd for boost, compared with 
24 (21%) of 112 recipients of BNT for 
both prime and boost (difference 21%, 
95% CI 8–33%). Similar increases were 
observed for chills, fatigue, headache, 
joint pain, malaise, and muscle ache 
(figure; appendix). There were no 
hospitalisations due to solicited 
symptoms, and most of this increase in 
reactogenicity was observed in the 48 h 
after immunisation (appendix).
Participants were advised that 
paracetamol might reduce vaccine 
side-effects but were not actively coun-
selled to medicate prophylactically. 
Paracetamol use in the 48 h post-boost 
vaccine was reported by 40 (36%) of 
112 recipients of ChAd for both prime 
and boost, 63 (57%) of 110 recipients 
of ChAd for prime and BNT for boost, 
48 (41%) of 117 recipients of BNT for 
both prime and boost, and 68 (60%) 
of 114 recipients of BNT for prime and 
ChAd for boost, thereby mirroring the 
reactogenicity pattern.
Haematology and biochemistry 
profiles were similar between hetero-
logous and homologous vaccine 
schedules, with all laboratory adverse 
events of grade 2 severity or less in 
the heterologous vaccine schedule, 
and no thrombocytopenia in any 
group at day 7 post-boost (appendix).
In this interim safety analysis, 
we found an increase in systemic 
reactogenicity after the boost 
dose reported by participants in 
heterologous vaccine schedules in 
comparison to homologous vaccine 
schedules, and this was accompanied 
by increased paracetamol usage. Of 
note, these data were obtained in 
participants aged 50 years and older, 
and reactogenicity might be higher 
in younger age groups4,5 for whom a 
mixed vaccination schedule is being 
advocated in Germany, France, Sweden, 
Norway, and Denmark among those 
who have received a ChAd prime 
dose, in light of concerns regarding 
thrombotic thrombo cytopenia after 
the first dose of ChAd.6
Pending availability of a more 
complete safety dataset and immuno-
genicity results for heterologous 
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prime-boost schedules (to be reported 
shortly), these data suggest that the 
two heterologous vaccine schedules in 
this trial might have some short-term 
disadvantages. Routine prophylactic 
use of paracetamol after immunisation 
could help mitigate these7 and is being 
studied in Com-COV participants 
receiving prime and boost vaccines 
at 12-week intervals. Regardless, it 
is reassuring that all reactogenicity 
symptoms were short lived, and there 
were no concerns from the limited 
haematology and biochemistry data 
available. Further studies evaluating 
heterologous prime-boost schedules, 
incorporating vaccines manufactured 
by Moderna and Novavax, are ongoing, 
and are crucial to informing the 
appropriateness of mixed COVID-19 
vaccine schedules.
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Figure: Severity of solicited local and systemic 
reactions in days 0–7 after vaccination with 
ChAdOx1 nCoV-19 (ChAd) or BNT162b2 (BNT), 
by prime and boost vaccination and by 
vaccination group, as self-reported in participant 
electronic diaries
ChAd/ChAd denotes a ChAd vaccine for prime and 
boost doses. ChAd/BNT denotes a ChAd vaccine for 
prime dose and a BNT vaccine for boost dose. 
BNT/BNT denotes a BNT vaccine for prime and 
boost doses. BNT/ChAd denotes a BNT for prime 
dose and a ChAd vaccine for boost dose. 
The severity presented is the participant’s highest 
severity across 7 days after vaccination for each 
solicited adverse event. Fever was categorised as 
mild (38·0°C to <38·5°C), moderate 
(38·5°C to <39°C), or severe (≥39·0°C). Feverish was 
a self-reported feeling of feverishness. For systemic 
symptoms, grading was classified as mild (easily 
tolerated with no limitation on normal activity), 
moderate (some limitation of daily activity), and 
severe (unable to perform normal daily activity). 
